Cart
×
Duchenne Newborn Screening Moves Forward: Celebrating Progress
The addition of Duchenne muscular dystrophy (DMD) to the Recommended Uniform Screening Panel (RUSP) marks a meaningful step forward in the effort to diagnose Duchenne earlier and connect families to care as soon as possible. For two decades, researchers and clinicians have worked toward earlier diagnosis of Duchenne, yet the average age of diagnosis has remained around four years old. This change will pave the way for more states to adopt universal newborn screening for Duchenne, and it reflects years of collaboration, research, and advocacy across the Duchenne community.
At CureDuchenne, we’re proud to have played a part in moving this effort forward—not only by championing the goal of earlier diagnosis, but by funding research that contributed to the RUSP approval.
In particular, we’re grateful to Dr. Richard Parad and his team at Brigham and Women’s Hospital (BWH), whose newborn screening pilot program offered valuable data and insights that helped shape the national conversation. Supported in part by a CureDuchenne grant, the BWH study offered supplemental newborn screening for Duchenne in a clinical setting and took a unique approach: using a one-sample testing method that led to a notably low false positive rate. That approach proved both efficient and family-centered—and is now helping inform best practices for future implementation.
Massachusetts, where the BWH pilot was conducted, is now preparing to implement statewide Duchenne newborn screening following the federal RUSP recommendation. While timelines vary by state, inclusion on the RUSP is expected to encourage broader adoption of Duchenne screening programs nationwide as states evaluate implementation pathways.
Dr. Parad and his team have published their findings in Prenatal Diagnosis and Muscle & Nerve and will continue to publish findings from the 18,000+ newborns screened in the BWH pilot. This research:
- Highlights trends suggesting expanded prenatal carrier screening may be reducing the incidence of Duchenne in some regions.
- Provides a new tool for clinicians to assess elevated CK levels and better distinguish birth-related causes from possible Duchenne diagnoses.
- Explores follow-up data on female carriers, a group that remains under-studied despite important implications for care and surveillance.
These insights not only support implementation of newborn screening—they reflect CureDuchenne’s broader mission to drive research that makes a tangible difference for individuals and families navigating this diagnosis.
We’re proud of the role we’ve played in helping advance this work and grateful to every family, researcher, and supporter who helped make it possible. With newborn screening on the horizon nationwide, we’re more committed than ever to ensuring that every individual diagnosed with Duchenne has access to timely care, information, and hope.
Learn more about the CureDuchenne-funded pilot:
Newborn screening initiative at Brigham and Women’s Hospital →
Related posts:
